董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Zacut | 男 | Chairman of the Board | 68 | 13.80万美元 | 未持股 | 2020-03-23 |
| Avner Hagai | 男 | Vice Chairman of the Board | 64 | 未披露 | 未持股 | 2020-03-23 |
| Gavriel Magen | 男 | Director | 60 | 未披露 | 未持股 | 2020-03-23 |
| Eti Mitrany | 女 | Director | 50 | 未披露 | 1.38 | 2020-03-23 |
| Karen Sarid | 女 | Director | 69 | 未披露 | 未持股 | 2020-03-23 |
| Yossi Ben Shalom | 男 | Director | 64 | 未披露 | 2.29 | 2020-03-23 |
| Orly Uri | 女 | Director | 61 | 未披露 | 未持股 | 2020-03-23 |
| Abraham Zangen | 男 | Director | 51 | 未披露 | 93.71 | 2020-03-23 |
| Avner Lushi | 男 | Director | 53 | 未披露 | 1.38 | 2020-03-23 |
| Karen Sarid | 女 | Director | 69 | 未披露 | 2.75 | 2020-03-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yiftach Roth | -- | Chief Scientist | 50 | 未披露 | 108.34 | 2020-03-23 |
| Moria Ankri | 女 | Vice President Research and Development | 36 | 16.90万美元 | 未持股 | 2020-03-23 |
| Amit Ginou | 男 | Vice President Field and Clinical Operations | 39 | 19.50万美元 | 9.97 | 2020-03-23 |
| Christopher R. von Jako | 男 | President and Chief Executive Officer | 51 | 未披露 | 12.50 | 2020-03-23 |
| Hadar Levy | 男 | Chief Financial Officer & Chief Operations Officer | 48 | 32.50万美元 | 37.29 | 2020-03-23 |
董事简历
中英对照 | 中文 | 英文- David Zacut
-
David Zacut自成立以来一直担任我们的董事会主席，并自2001年5月以来一直为Brain研究与开发服务公司提供咨询服务。Zacut博士从1983年开始在哈大沙医院（Hadassah Hospital）担任高级执业医师，并从1994年到2003年担任多家大型医疗中心的常务董事。此外，Zacut博士还担任几家私营公司的董事，其中包括Brain研究与开发服务公司。Zacut博士拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）医学博士学位。
David Zacut has served as our Chairman of the Board of Directors since our inception and has been providing consulting services to Brain Research and Development Services since May 2001. Since 1983 Dr. Zacut has been working as a senior practicing physician at Hadassah Hospital, and from 1994 through 2003 he served as a managing director of several large medical centers. In addition, Dr. Zacut serves as a director of several private companies, including Brain Research and Development Services. Dr. Zacut holds an M.D. degree from the Hebrew University of Jerusalem. - David Zacut自成立以来一直担任我们的董事会主席，并自2001年5月以来一直为Brain研究与开发服务公司提供咨询服务。Zacut博士从1983年开始在哈大沙医院（Hadassah Hospital）担任高级执业医师，并从1994年到2003年担任多家大型医疗中心的常务董事。此外，Zacut博士还担任几家私营公司的董事，其中包括Brain研究与开发服务公司。Zacut博士拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）医学博士学位。
- David Zacut has served as our Chairman of the Board of Directors since our inception and has been providing consulting services to Brain Research and Development Services since May 2001. Since 1983 Dr. Zacut has been working as a senior practicing physician at Hadassah Hospital, and from 1994 through 2003 he served as a managing director of several large medical centers. In addition, Dr. Zacut serves as a director of several private companies, including Brain Research and Development Services. Dr. Zacut holds an M.D. degree from the Hebrew University of Jerusalem.
- Avner Hagai
-
Avner Hagai自2006年11月以来一直担任我们的董事Vice Chairman of the Board。他曾担任多家公司的董事，包括Hofit Kibbutz Kinneret Ltd.（塑料制造商）（2010年以来），以及Prisma F.S.Ltd.（建筑管理公司）（2002年以来）。他成立A.A.Glass Ltd.（汽车玻璃和服务公司），在那里他曾一直担任董事（1984年以来）。
Avner Hagai has served as our Vice Chairman of the Board of Directors since November 2006. He serves as a director at several companies, including at Hofit Kibbutz Kinneret Ltd., a plastics manufacturer, where he has served since 2010 and at Prisma F.S. Ltd., a building management company, where he has served since 2002. Mr. Hagai established A.A. Glass Ltd., an automotive glass and services company, where he has served as a director since 1984. - Avner Hagai自2006年11月以来一直担任我们的董事Vice Chairman of the Board。他曾担任多家公司的董事，包括Hofit Kibbutz Kinneret Ltd.（塑料制造商）（2010年以来），以及Prisma F.S.Ltd.（建筑管理公司）（2002年以来）。他成立A.A.Glass Ltd.（汽车玻璃和服务公司），在那里他曾一直担任董事（1984年以来）。
- Avner Hagai has served as our Vice Chairman of the Board of Directors since November 2006. He serves as a director at several companies, including at Hofit Kibbutz Kinneret Ltd., a plastics manufacturer, where he has served since 2010 and at Prisma F.S. Ltd., a building management company, where he has served since 2002. Mr. Hagai established A.A. Glass Ltd., an automotive glass and services company, where he has served as a director since 1984.
- Gavriel Magen
-
Gavriel Magen自2006年12月以来一直担任我们的董事。Magen先生从2009年1月1日开始一直担任Polybid Ltd.的首席执行官，该公司是以色列最大的可膨胀聚苯乙烯EPS生产商。从2007年到2009年，Magen先生担任Plassim Ltd.的首席执行官，这是一家为众多应用程序制造管道的以色列公司，从2000年到2007年，他担任Oran Palmach Subba Agricultural Cooperative Society Ltd.的首席执行官，这是一家以色列的安全生产商，强化和强化玻璃。Magen先生拥有以色列赫费尔山谷Ruppin学术中心的工商管理学士学位。他居住在Har Adar。
Gavriel Magen has served as our Director since December 2006. Mr. Magen has been the Chief Executive Officer of Polybid Ltd., the largest Expandable Polystyrene EPS producer in Israel, since January 1 2009. From 2007 to 2009 Mr. Magen served as the Chief Executive Officer of Plassim Ltd., an Israeli company that manufactures pipes for numerous applications and from 2000 to 2007 he served as the Chief Executive Officer of Oran Palmach Subba Agricultural Cooperative Society Ltd., an Israeli producer of safety, strengthened and reinforced glass. Mr. Magen holds a BA in Business Administration from the Ruppin Academic Center in Hefer Valley, Israel. He resides in Har Adar. - Gavriel Magen自2006年12月以来一直担任我们的董事。Magen先生从2009年1月1日开始一直担任Polybid Ltd.的首席执行官，该公司是以色列最大的可膨胀聚苯乙烯EPS生产商。从2007年到2009年，Magen先生担任Plassim Ltd.的首席执行官，这是一家为众多应用程序制造管道的以色列公司，从2000年到2007年，他担任Oran Palmach Subba Agricultural Cooperative Society Ltd.的首席执行官，这是一家以色列的安全生产商，强化和强化玻璃。Magen先生拥有以色列赫费尔山谷Ruppin学术中心的工商管理学士学位。他居住在Har Adar。
- Gavriel Magen has served as our Director since December 2006. Mr. Magen has been the Chief Executive Officer of Polybid Ltd., the largest Expandable Polystyrene EPS producer in Israel, since January 1 2009. From 2007 to 2009 Mr. Magen served as the Chief Executive Officer of Plassim Ltd., an Israeli company that manufactures pipes for numerous applications and from 2000 to 2007 he served as the Chief Executive Officer of Oran Palmach Subba Agricultural Cooperative Society Ltd., an Israeli producer of safety, strengthened and reinforced glass. Mr. Magen holds a BA in Business Administration from the Ruppin Academic Center in Hefer Valley, Israel. He resides in Har Adar.
- Eti Mitrany
-
Eti Mitrany自2016年6月以来一直担任我们的董事，目前担任薪酬委员会主席和审计委员会成员。米特拉尼此前自2012年起担任梯瓦制药公司（Teva Pharmaceuticals）企业经济部高级副总裁，主管，全面负责梯瓦制药的业务规划和分析。在此之前，Mitrany女士曾在Teva担任多个职位，包括Specialty R&D的首席财务官，以及全球品牌业务的首席财务官兼财务规划与分析总监。Mitrany女士于1995年加入Teva，担任Copaxone（Teva治疗多发性硬化症的第一个创新产品）的财务分析师。Mitrany女士在特拉维夫大学（Tel-Aviv University）获得经济学学士学位和金融工商管理硕士学位。
Eti Mitrany has served as our Director since June 2016 and currently serves as chairperson of our compensation committee and a member of our audit committee. Ms. Mitrany previously served as Senior Vice President, Head of the Corporate Economic Department at Teva Pharmaceuticals since 2012 with global responsibility for Teva’s business planning and analysis. Prior to that, Ms. Mitrany held various positions in Teva, including CFO of specialty R&D, and CFO and Director of Financial Planning & Analysis of the global branded business. Ms. Mitrany joined Teva in 1995 as a financial analyst of Copaxone-the first innovative product of Teva for the treatment of multiple sclerosis. Ms. Mitrany received her BA in Economics and MBA in Finance, both from Tel-Aviv University. - Eti Mitrany自2016年6月以来一直担任我们的董事，目前担任薪酬委员会主席和审计委员会成员。米特拉尼此前自2012年起担任梯瓦制药公司（Teva Pharmaceuticals）企业经济部高级副总裁，主管，全面负责梯瓦制药的业务规划和分析。在此之前，Mitrany女士曾在Teva担任多个职位，包括Specialty R&D的首席财务官，以及全球品牌业务的首席财务官兼财务规划与分析总监。Mitrany女士于1995年加入Teva，担任Copaxone（Teva治疗多发性硬化症的第一个创新产品）的财务分析师。Mitrany女士在特拉维夫大学（Tel-Aviv University）获得经济学学士学位和金融工商管理硕士学位。
- Eti Mitrany has served as our Director since June 2016 and currently serves as chairperson of our compensation committee and a member of our audit committee. Ms. Mitrany previously served as Senior Vice President, Head of the Corporate Economic Department at Teva Pharmaceuticals since 2012 with global responsibility for Teva’s business planning and analysis. Prior to that, Ms. Mitrany held various positions in Teva, including CFO of specialty R&D, and CFO and Director of Financial Planning & Analysis of the global branded business. Ms. Mitrany joined Teva in 1995 as a financial analyst of Copaxone-the first innovative product of Teva for the treatment of multiple sclerosis. Ms. Mitrany received her BA in Economics and MBA in Finance, both from Tel-Aviv University.
- Karen Sarid
-
Karen Sarid自2017年12月起担任我们的董事，目前担任我们的审计委员会主席。2014年3月至2017年7月，萨里德女士担任Syneron MedicalLtd.美容牙科副总裁兼中国活动主席2012年1月至2013年8月，Sarid女士担任Alma Lasers Ltd.的总裁。Sarid女士目前担任EVA Visual Ltd.的董事。她持有the University of Haifa的经济学和会计学学士学位。
Karen Sarid has served as our Director since December 2017 and currently serves as chairperson of our audit committee. Between March 2014 and July 2017 Ms. Sarid served as VP Beauty and Dental and as Chairman of China activities at Syneron Medical Ltd. Between January 2012 and August 2013 Ms. Sarid served as President of Alma Lasers Ltd. Ms. Sarid currently serves as a director of Eva Visual Ltd. She holds a BA in Economics and Accounting from the University of Haifa. - Karen Sarid自2017年12月起担任我们的董事，目前担任我们的审计委员会主席。2014年3月至2017年7月，萨里德女士担任Syneron MedicalLtd.美容牙科副总裁兼中国活动主席2012年1月至2013年8月，Sarid女士担任Alma Lasers Ltd.的总裁。Sarid女士目前担任EVA Visual Ltd.的董事。她持有the University of Haifa的经济学和会计学学士学位。
- Karen Sarid has served as our Director since December 2017 and currently serves as chairperson of our audit committee. Between March 2014 and July 2017 Ms. Sarid served as VP Beauty and Dental and as Chairman of China activities at Syneron Medical Ltd. Between January 2012 and August 2013 Ms. Sarid served as President of Alma Lasers Ltd. Ms. Sarid currently serves as a director of Eva Visual Ltd. She holds a BA in Economics and Accounting from the University of Haifa.
- Yossi Ben Shalom
-
Yossi Ben Shalom自2018年12月起担任我们的董事。Ben Shalom先生是D.B.S.I公司的联合创始人，D.B.S.I公司是一家私人投资公司，专门投资于全球定位于高增长或通过并购进行大规模扩张的成熟公司。因此，Ben Shalom先生担任Pointer TelocationLtd.的董事长纳斯达克股票代码:PNTR，RADA（NASDAQ:RADA）和Shagrir Group Car Services Ltd.（TASE:SHGR）。他还担任Taldor Computer Systems-1986Ltd.（TASE:TALD）、Eldan Cargo Ltd.、The8Note Production&Distribution Ltd.、Car2Go Ltd.、Matzman et Merutz Milenum Ltd.和Kafrit Industries-1993Ltd.的董事。Ben Shalom先生从1998年到2000年担任Koor Industries Ltd.的执行Vice President和首席财务官。在此之前，Ben-Shalom先生在1994年至1998年期间担任Tadiran Ltd.的首席财务官。Ben Shalom先生拥有特拉维夫大学（Tel Aviv University）经济学学士学位和工商管理硕士学位。
Yossi Ben Shalom has served as our Director since December 2018. Mr. Ben Shalom is a co-founder of D.B.S.I, a private investment company specializing in investments in mature companies that are positioned globally for high growth or built for vast expansion through M&As. As such, Mr. Ben Shalom serves as the Chairman of Pointer Telocation Ltd. Nasdaq: PNTR, Rada (Nasdaq: RADA) and Shagrir Group Car Services Ltd. (TASE: SHGR). He also serves as a director at Taldor Computer Systems -1986 Ltd. (TASE: TALD), Eldan Cargo Ltd., The 8 Note Production & Distribution Ltd., Car 2 Go Ltd., Matzman Et Merutz Milenum Ltd. and Kafrit Industries -1993 Ltd. Mr. Ben Shalom was Executive Vice President and Chief Financial Officer of Koor Industries Ltd. from 1998 through to 2000. Before that, Mr. Ben-Shalom served as Chief Financial Officer of Tadiran Ltd. between 1994 and 1998. Mr. Ben Shalom holds a BA in Economics and an MA in Business Administration both from Tel Aviv University. - Yossi Ben Shalom自2018年12月起担任我们的董事。Ben Shalom先生是D.B.S.I公司的联合创始人，D.B.S.I公司是一家私人投资公司，专门投资于全球定位于高增长或通过并购进行大规模扩张的成熟公司。因此，Ben Shalom先生担任Pointer TelocationLtd.的董事长纳斯达克股票代码:PNTR，RADA（NASDAQ:RADA）和Shagrir Group Car Services Ltd.（TASE:SHGR）。他还担任Taldor Computer Systems-1986Ltd.（TASE:TALD）、Eldan Cargo Ltd.、The8Note Production&Distribution Ltd.、Car2Go Ltd.、Matzman et Merutz Milenum Ltd.和Kafrit Industries-1993Ltd.的董事。Ben Shalom先生从1998年到2000年担任Koor Industries Ltd.的执行Vice President和首席财务官。在此之前，Ben-Shalom先生在1994年至1998年期间担任Tadiran Ltd.的首席财务官。Ben Shalom先生拥有特拉维夫大学（Tel Aviv University）经济学学士学位和工商管理硕士学位。
- Yossi Ben Shalom has served as our Director since December 2018. Mr. Ben Shalom is a co-founder of D.B.S.I, a private investment company specializing in investments in mature companies that are positioned globally for high growth or built for vast expansion through M&As. As such, Mr. Ben Shalom serves as the Chairman of Pointer Telocation Ltd. Nasdaq: PNTR, Rada (Nasdaq: RADA) and Shagrir Group Car Services Ltd. (TASE: SHGR). He also serves as a director at Taldor Computer Systems -1986 Ltd. (TASE: TALD), Eldan Cargo Ltd., The 8 Note Production & Distribution Ltd., Car 2 Go Ltd., Matzman Et Merutz Milenum Ltd. and Kafrit Industries -1993 Ltd. Mr. Ben Shalom was Executive Vice President and Chief Financial Officer of Koor Industries Ltd. from 1998 through to 2000. Before that, Mr. Ben-Shalom served as Chief Financial Officer of Tadiran Ltd. between 1994 and 1998. Mr. Ben Shalom holds a BA in Economics and an MA in Business Administration both from Tel Aviv University.
- Orly Uri
-
Orly Uri自2018年12月起担任我们的董事。她此前曾担任我们的外部董事、财务委员会成员，以及我们的审计委员会和薪酬委员会的主席（从2007年到2016年4月）。Uri女士是以色列国内外梦百合部门各机构、组织和公司的财务、战略和组织顾问。此前，她曾担任Leumit HMO的规划、预算和经济部主管（1996年至2003年）。她的职业生涯始于Klalit HMO，于1986年至1999年间担任多种财务和审计职务。2000年至2004年，Uri女士是Ben Gurion University和Ashkelon University的客座讲师。Uri女士获得了经济学和工商管理学士学位以及理学硕士学位。工业和管理工程-医学管理，均来自Ben Gurion University。
Orly Uri has served as our Director since December 2018. She previously served as our external director, member of our finance committee and chairperson of our audit committee and our compensation committee from 2007 until April 2016. Ms. Uri is a financial, strategic and organizational advisor to institutions, organizations and corporations in the healthcare sector in Israel and abroad. Prior to that she served as head of planning, budgeting and economics department in Leumit HMO between 1996 and 2003. She started her career in Klalit HMO in various financial and audit positions between 1986 and 1999. Ms. Uri was a guest lecturer in Ben Gurion University and in Ashkelon University between 2000 and 2004. Ms. Uri earned a BA in Economics and Business Administration and a M.Sc. in Industrial and Management Engineering-Medical Management, both from Ben Gurion University. - Orly Uri自2018年12月起担任我们的董事。她此前曾担任我们的外部董事、财务委员会成员，以及我们的审计委员会和薪酬委员会的主席（从2007年到2016年4月）。Uri女士是以色列国内外梦百合部门各机构、组织和公司的财务、战略和组织顾问。此前，她曾担任Leumit HMO的规划、预算和经济部主管（1996年至2003年）。她的职业生涯始于Klalit HMO，于1986年至1999年间担任多种财务和审计职务。2000年至2004年，Uri女士是Ben Gurion University和Ashkelon University的客座讲师。Uri女士获得了经济学和工商管理学士学位以及理学硕士学位。工业和管理工程-医学管理，均来自Ben Gurion University。
- Orly Uri has served as our Director since December 2018. She previously served as our external director, member of our finance committee and chairperson of our audit committee and our compensation committee from 2007 until April 2016. Ms. Uri is a financial, strategic and organizational advisor to institutions, organizations and corporations in the healthcare sector in Israel and abroad. Prior to that she served as head of planning, budgeting and economics department in Leumit HMO between 1996 and 2003. She started her career in Klalit HMO in various financial and audit positions between 1986 and 1999. Ms. Uri was a guest lecturer in Ben Gurion University and in Ashkelon University between 2000 and 2004. Ms. Uri earned a BA in Economics and Business Administration and a M.Sc. in Industrial and Management Engineering-Medical Management, both from Ben Gurion University.
- Abraham Zangen
-
Abraham Zangen是以色列本古里安大学大脑刺激和行为实验室的负责人，也是心理生物学大脑项目的主席。他的研究旨在识别和理解精神疾病（主要是抑郁症，成瘾和多动症）中改变的神经可塑性，利用脑刺激和成像技术探索机制和潜在的临床应用。他与Yiftach Roth博士共同开发了作为Brainsway平台技术的Deep TMS线圈。Zangen教授发表了150多篇同行评议文章、评论和书籍章节。他曾因其科学成就获得众多奖项，包括伦敦医学未来创新奖、Sieratzki神经科学进步奖和the Technion的朱卢丹奖。他还获得了几项杰出的研究补助金，包括美国国立卫生研究院，H2020和以色列科学基金会。
Abraham Zangen is the Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University in Israel. His research is directed at identifying and understanding altered neuroplasticity in psychiatric disorders, primarily depression, addiction and ADHD, utilizing brain stimulation and imaging techniques to explore mechanisms and potential clinical applications. He co-developed, along with Dr. Yiftach Roth, the Deep TMS coil which serves as Brainsway’s platform technology. Professor Zangen has published over 150 peer reviewed articles, reviews and book chapters. He has been awarded numerous prizes for his scientific achievements, including the Medical Futures Innovation Award in London, the Sieratzki Prize for Advances in Neuroscience and the Juludan Prize at the Technion. He has also received several distinguished research grants, including from the National Institutes of Health, H2020 and the Israel Science Foundation. - Abraham Zangen是以色列本古里安大学大脑刺激和行为实验室的负责人，也是心理生物学大脑项目的主席。他的研究旨在识别和理解精神疾病（主要是抑郁症，成瘾和多动症）中改变的神经可塑性，利用脑刺激和成像技术探索机制和潜在的临床应用。他与Yiftach Roth博士共同开发了作为Brainsway平台技术的Deep TMS线圈。Zangen教授发表了150多篇同行评议文章、评论和书籍章节。他曾因其科学成就获得众多奖项，包括伦敦医学未来创新奖、Sieratzki神经科学进步奖和the Technion的朱卢丹奖。他还获得了几项杰出的研究补助金，包括美国国立卫生研究院，H2020和以色列科学基金会。
- Abraham Zangen is the Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University in Israel. His research is directed at identifying and understanding altered neuroplasticity in psychiatric disorders, primarily depression, addiction and ADHD, utilizing brain stimulation and imaging techniques to explore mechanisms and potential clinical applications. He co-developed, along with Dr. Yiftach Roth, the Deep TMS coil which serves as Brainsway’s platform technology. Professor Zangen has published over 150 peer reviewed articles, reviews and book chapters. He has been awarded numerous prizes for his scientific achievements, including the Medical Futures Innovation Award in London, the Sieratzki Prize for Advances in Neuroscience and the Juludan Prize at the Technion. He has also received several distinguished research grants, including from the National Institutes of Health, H2020 and the Israel Science Foundation.
- Avner Lushi
-
Avner Lushi自2020年1月起担任我们的董事，目前是我们审计委员会的成员。他曾共同创立广州中以生物产业投资基金GIBF，专注于将以色列和西方生命科学公司引入中国市场，在那里他也曾担任管理合伙人兼首席执行官。2004年至2015年，Lushi先生担任生命科学风险投资基金Israel梦百合Ventures（IHCV）的合伙人兼董事总经理。从2001年到2005年，他共同创立并担任Life Sciences Transaction Support Ltd.（LTS）（普华永道的子公司，处理生命科学投资银行业务）的首席执行官。Lushi先生曾在七家上市公司担任独立董事，最后活跃的两家是Raval ICS Ltd.和Ram-On Investments and Holdings-1999Ltd.。此外，他担任几家私人公司的董事会成员，作为他在GIBF的角色的一部分。在转向私营部门之前的1997年至2001年，他在以色列总理办公室和以色列最高法院担任越来越高级的职务。Lushi先生拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）法学硕士学位，海法大学（Haifa University）法学学士学位和经济学学士学位。
Avner Lushi, 58, was appointed as a director of New Silexion effective upon the consummation of the Biness Combination. His experience of over 20 years and skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr. Lhi co founded Guangzhou Sino Israel Bio indtry Investment Fund (GIBF), which currently includes two approximately $100 million funds foced on introducing Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner & CEO of the GP since 2016. From 2004 to 2015, Mr. Lhi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV), a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr. Lhi was the Co Founder & CEO of Life Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lhi has served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF. From 1997 to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and the Israeli Supreme Ct. Mr. Lhi holds an LLM in Law from the Hebrew University of Jeralem, LLB in Law and a BA in Economics from the Haifa University. - Avner Lushi自2020年1月起担任我们的董事，目前是我们审计委员会的成员。他曾共同创立广州中以生物产业投资基金GIBF，专注于将以色列和西方生命科学公司引入中国市场，在那里他也曾担任管理合伙人兼首席执行官。2004年至2015年，Lushi先生担任生命科学风险投资基金Israel梦百合Ventures（IHCV）的合伙人兼董事总经理。从2001年到2005年，他共同创立并担任Life Sciences Transaction Support Ltd.（LTS）（普华永道的子公司，处理生命科学投资银行业务）的首席执行官。Lushi先生曾在七家上市公司担任独立董事，最后活跃的两家是Raval ICS Ltd.和Ram-On Investments and Holdings-1999Ltd.。此外，他担任几家私人公司的董事会成员，作为他在GIBF的角色的一部分。在转向私营部门之前的1997年至2001年，他在以色列总理办公室和以色列最高法院担任越来越高级的职务。Lushi先生拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）法学硕士学位，海法大学（Haifa University）法学学士学位和经济学学士学位。
- Avner Lushi, 58, was appointed as a director of New Silexion effective upon the consummation of the Biness Combination. His experience of over 20 years and skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr. Lhi co founded Guangzhou Sino Israel Bio indtry Investment Fund (GIBF), which currently includes two approximately $100 million funds foced on introducing Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner & CEO of the GP since 2016. From 2004 to 2015, Mr. Lhi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV), a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr. Lhi was the Co Founder & CEO of Life Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lhi has served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF. From 1997 to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and the Israeli Supreme Ct. Mr. Lhi holds an LLM in Law from the Hebrew University of Jeralem, LLB in Law and a BA in Economics from the Haifa University.
- Karen Sarid
-
Karen Sarid，2001年12月起担任本公司董事，现为审核委员会和薪酬委员会的成员。2014年3月以来，她是Syneron Medical Israel的美容与牙科业务副总裁；她还从2014年1月起，担任生发行业公司Hairstetics的执行董事长。2012年1月至2013年8月，她是Alma Lasers的总裁。2009-2010，她担任Syneron Medical Israel的总裁、总经理；2007-2009，担任Galil Medical Israel的总经理。此前，她从2005年起担任Orex Computed Radiography 的总经理，这是一个柯达旗下公司，专注于数字化X射线市场的X射线成像系统。在此之前，她从2000年9月起，担任Orex Computed Radiography的首席运营官兼首席财务官。1999年9月至2000年9月，他是Forsoft的首席财务官、董事，这是的Formula Group子公司，从事提供软件解决方案。1996年至1999年8月，她担任ESC Medical Systems的首席财务官、董事，这是纳斯达克上市的医疗激光生产公司。1993-1996，她担任本公司的首席财务官。她也是Oridion Systems 和 Gilat Satellite Networks的董事。2012年9月起，她担任 Medical Compression Systems MCS的董事、审核委员会成员。她获得了Haifa University的经济与会计学士学位，在1998年被以色列首席财务官协会评为年度首席财务官。
Karen Sarid has served as a director of our Company since December 2001 and is a member of our Audit Committee and Compensation Committee. Ms. Sarid serves as VP Beauty and Dental Business of Syneron Medical Israel since March 2014. Ms. Sarid also serves as Active Chairman of Hairstetics, a company in the field of hair restoration, since January 2014. Ms. Sarid served as President of Alma Lasers Ltd from January 2012 until August 2013. Ms. Sarid served as President and General Manager of Syneron Medical Israel from 2009 to 2010. Ms. Sarid served as the General Manager of Galil Medical Israel from 2007 to 2009. Prior to that and from 2005 Ms. Sarid served as a General Manager of Orex Computed Radiography Ltd., a Kodak Company focusing on radiography systems for the digital x-ray market. Prior to that and from September 2000 Ms. Sarid held the position of Chief Operating Officer and Chief Financial Officer at Orex Computed Radiography Ltd. From September 1999 until September 2000 Ms. Sarid was Chief Financial Officer and a member of the Board of Directors of Forsoft Ltd., a software solutions provider and a subsidiary of the Formula Group. From 1996 until August 1999 Ms. Sarid was Chief Financial Officer and a member of the Board of Directors of ESC Medical Systems Ltd., a medical laser manufacturer that was listed on the NASDAQ Stock Market. Ms. Sarid was Chief Financial Officer of our company from 1993 through 1996. Ms. Sarid also serves as a director of Oridion Systems Ltd. and Gilat Satellite Networks Ltd. Since September 2012 Ms. Sarid also serves as a director and a member of the audit committee of Medical Compression Systems MCS. Ms. Sarid holds a B.A. degree in Economics and Accounting from Haifa University, and was awarded the Chief Financial Officer of the Year award in 1998 by the Association of Chief Financial Officers in Israel. - Karen Sarid，2001年12月起担任本公司董事，现为审核委员会和薪酬委员会的成员。2014年3月以来，她是Syneron Medical Israel的美容与牙科业务副总裁；她还从2014年1月起，担任生发行业公司Hairstetics的执行董事长。2012年1月至2013年8月，她是Alma Lasers的总裁。2009-2010，她担任Syneron Medical Israel的总裁、总经理；2007-2009，担任Galil Medical Israel的总经理。此前，她从2005年起担任Orex Computed Radiography 的总经理，这是一个柯达旗下公司，专注于数字化X射线市场的X射线成像系统。在此之前，她从2000年9月起，担任Orex Computed Radiography的首席运营官兼首席财务官。1999年9月至2000年9月，他是Forsoft的首席财务官、董事，这是的Formula Group子公司，从事提供软件解决方案。1996年至1999年8月，她担任ESC Medical Systems的首席财务官、董事，这是纳斯达克上市的医疗激光生产公司。1993-1996，她担任本公司的首席财务官。她也是Oridion Systems 和 Gilat Satellite Networks的董事。2012年9月起，她担任 Medical Compression Systems MCS的董事、审核委员会成员。她获得了Haifa University的经济与会计学士学位，在1998年被以色列首席财务官协会评为年度首席财务官。
- Karen Sarid has served as a director of our Company since December 2001 and is a member of our Audit Committee and Compensation Committee. Ms. Sarid serves as VP Beauty and Dental Business of Syneron Medical Israel since March 2014. Ms. Sarid also serves as Active Chairman of Hairstetics, a company in the field of hair restoration, since January 2014. Ms. Sarid served as President of Alma Lasers Ltd from January 2012 until August 2013. Ms. Sarid served as President and General Manager of Syneron Medical Israel from 2009 to 2010. Ms. Sarid served as the General Manager of Galil Medical Israel from 2007 to 2009. Prior to that and from 2005 Ms. Sarid served as a General Manager of Orex Computed Radiography Ltd., a Kodak Company focusing on radiography systems for the digital x-ray market. Prior to that and from September 2000 Ms. Sarid held the position of Chief Operating Officer and Chief Financial Officer at Orex Computed Radiography Ltd. From September 1999 until September 2000 Ms. Sarid was Chief Financial Officer and a member of the Board of Directors of Forsoft Ltd., a software solutions provider and a subsidiary of the Formula Group. From 1996 until August 1999 Ms. Sarid was Chief Financial Officer and a member of the Board of Directors of ESC Medical Systems Ltd., a medical laser manufacturer that was listed on the NASDAQ Stock Market. Ms. Sarid was Chief Financial Officer of our company from 1993 through 1996. Ms. Sarid also serves as a director of Oridion Systems Ltd. and Gilat Satellite Networks Ltd. Since September 2012 Ms. Sarid also serves as a director and a member of the audit committee of Medical Compression Systems MCS. Ms. Sarid holds a B.A. degree in Economics and Accounting from Haifa University, and was awarded the Chief Financial Officer of the Year award in 1998 by the Association of Chief Financial Officers in Israel.
高管简历
中英对照 | 中文 | 英文- Yiftach Roth
Yiftach Roth是我们的科学奠基人之一，也是深度TMS技术的主要发明者。Roth博士自2006年5月以来担任我们的研究与开发经理，自2006年11月以来担任董事会成员。Roth博士于2010年成为我们的首席科学家。Roth从2003年到2006年在Tel Hashomer Chaim Sheba Medical Center先进技术中心担任磁共振成像MRI领域研究员。Roth博士持有B.SC.和M.SC.Tel Aviv University物理学学位和医学物理学博士学位。
Yiftach Roth is one of our scientific founders and key inventors of the Deep TMS technology. Dr. Roth has served as our Research and Development Manager since May 2006 and as a member of the Board of Directors since November 2006. In 2010 Dr. Roth became our Chief Scientist. From 2003 through 2006 Dr. Roth worked in the Advanced Technology Center of the Chaim Sheba Medical Center at Tel Hashomer as a researcher in the field of Magnetic Resonance Imaging MRI. Dr. Roth holds B.Sc. and M.Sc. degrees in Physics and a Ph.D. in Medical Physics from Tel Aviv University.- Yiftach Roth是我们的科学奠基人之一，也是深度TMS技术的主要发明者。Roth博士自2006年5月以来担任我们的研究与开发经理，自2006年11月以来担任董事会成员。Roth博士于2010年成为我们的首席科学家。Roth从2003年到2006年在Tel Hashomer Chaim Sheba Medical Center先进技术中心担任磁共振成像MRI领域研究员。Roth博士持有B.SC.和M.SC.Tel Aviv University物理学学位和医学物理学博士学位。
- Yiftach Roth is one of our scientific founders and key inventors of the Deep TMS technology. Dr. Roth has served as our Research and Development Manager since May 2006 and as a member of the Board of Directors since November 2006. In 2010 Dr. Roth became our Chief Scientist. From 2003 through 2006 Dr. Roth worked in the Advanced Technology Center of the Chaim Sheba Medical Center at Tel Hashomer as a researcher in the field of Magnetic Resonance Imaging MRI. Dr. Roth holds B.Sc. and M.Sc. degrees in Physics and a Ph.D. in Medical Physics from Tel Aviv University.
- Moria Ankri
Moria Ankri自2017年9月起担任研究与开发Vice President。在担任研究与开发Vice President之前，Ankri女士于2010年至2017年担任公司生物医学发展部经理和公司研究与开发项目经理。Ankri女士拥有学士学位。耶路撒冷理工学院（Jerusalem College of Technology）生物医学工程学士学位，以及工商管理硕士学位。耶路撒冷希伯来大学神经生物学研究学士学位。
Moria Ankri has served as our Vice President of Research and Development since September 2017. Prior to her service as a Vice President of Research and Development, from 2010 to 2017 Ms. Ankri served as a manager at the Biomedical Development Department of our Company and as a research and development project manager at our Company. Ms. Ankri holds a B.Sc. in Biomedical Engineering from the Jerusalem College of Technology, and and a B.Sc. in neurobiology studies at the Hebrew University of Jerusalem.- Moria Ankri自2017年9月起担任研究与开发Vice President。在担任研究与开发Vice President之前，Ankri女士于2010年至2017年担任公司生物医学发展部经理和公司研究与开发项目经理。Ankri女士拥有学士学位。耶路撒冷理工学院（Jerusalem College of Technology）生物医学工程学士学位，以及工商管理硕士学位。耶路撒冷希伯来大学神经生物学研究学士学位。
- Moria Ankri has served as our Vice President of Research and Development since September 2017. Prior to her service as a Vice President of Research and Development, from 2010 to 2017 Ms. Ankri served as a manager at the Biomedical Development Department of our Company and as a research and development project manager at our Company. Ms. Ankri holds a B.Sc. in Biomedical Engineering from the Jerusalem College of Technology, and and a B.Sc. in neurobiology studies at the Hebrew University of Jerusalem.
- Amit Ginou
Amit Ginou自2013年10月以来一直担任我们的现场和临床运营Vice President。此前，Ginou先生从2008年11月到2013年10月担任我公司临床试验经理。Ginou先生拥有工商管理硕士学位。Bar Ilan University神经科学学士学位和Bar Ilan University法律硕士学位。
Amit Ginou has served as our Vice President of Field and Clinical Operations since October 2013. Previously, Mr. Ginou served as the Clinical Trials Manager of our Company from November 2008 to October 2013. Mr. Ginou holds a B.Sc. in Neuroscience from Bar Ilan University and a MA degree in Law from Bar Ilan University.- Amit Ginou自2013年10月以来一直担任我们的现场和临床运营Vice President。此前，Ginou先生从2008年11月到2013年10月担任我公司临床试验经理。Ginou先生拥有工商管理硕士学位。Bar Ilan University神经科学学士学位和Bar Ilan University法律硕士学位。
- Amit Ginou has served as our Vice President of Field and Clinical Operations since October 2013. Previously, Mr. Ginou served as the Clinical Trials Manager of our Company from November 2008 to October 2013. Mr. Ginou holds a B.Sc. in Neuroscience from Bar Ilan University and a MA degree in Law from Bar Ilan University.
- Christopher R. von Jako
ChristopherR.von Jako自2020年1月1日起担任我们的总裁兼首席执行官。最近，Von Jako博士担任Dynatronics Corporation的首席执行官，该公司是一家上市的医疗设备公司，专注于高质量的恢复性产品。任职Dynatronics公司之前，他曾担任其他公司的总裁兼首席执行官，包括NinePoint Medical，Inc.、Neurotherm，Inc.。职业生涯早期，他曾担任其他领先的医疗设备公司的高级职务，包括Integra LifeSciences公司、Covidien公司、Medtronic公司、Radionics公司。Von Jako博士拥有P&233；CS大学生物医学科学博士学位，麻省理工学院核工程系放射科学与技术硕士学位，贝茨学院物理学和数学双学士学位。他居住在马萨诸塞州林菲尔德，并继续担任NinePoint Medical，Inc.和NView Medical Inc.的董事会独立董事。
Christopher R. von Jako serves as our president and chief executive officer since January 1 2020. Most recently, Dr. von Jako served as CEO of Dynatronics Corporation, a publicly-traded medical device company focusing on high-quality restorative products. Prior to Dynatronics, he served as President and CEO of other companies including NinePoint Medical, Inc. and NeuroTherm, Inc. Earlier in his career, he held increasingly senior roles with other leading medical device companies, including Integra LifeSciences, Covidien, Medtronic, and Radionics. Dr. von Jako holds a Ph.D. in Biomedical Sciences from the University of Pécs, a M.S. degree in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology, and a double B.S. degree in Physics and Mathematics from Bates College. He resides in Lynnfield, Massachusetts and continues to serve as an independent director on the boards of NinePoint Medical, Inc. and nView medical Inc.- ChristopherR.von Jako自2020年1月1日起担任我们的总裁兼首席执行官。最近，Von Jako博士担任Dynatronics Corporation的首席执行官，该公司是一家上市的医疗设备公司，专注于高质量的恢复性产品。任职Dynatronics公司之前，他曾担任其他公司的总裁兼首席执行官，包括NinePoint Medical，Inc.、Neurotherm，Inc.。职业生涯早期，他曾担任其他领先的医疗设备公司的高级职务，包括Integra LifeSciences公司、Covidien公司、Medtronic公司、Radionics公司。Von Jako博士拥有P&233；CS大学生物医学科学博士学位，麻省理工学院核工程系放射科学与技术硕士学位，贝茨学院物理学和数学双学士学位。他居住在马萨诸塞州林菲尔德，并继续担任NinePoint Medical，Inc.和NView Medical Inc.的董事会独立董事。
- Christopher R. von Jako serves as our president and chief executive officer since January 1 2020. Most recently, Dr. von Jako served as CEO of Dynatronics Corporation, a publicly-traded medical device company focusing on high-quality restorative products. Prior to Dynatronics, he served as President and CEO of other companies including NinePoint Medical, Inc. and NeuroTherm, Inc. Earlier in his career, he held increasingly senior roles with other leading medical device companies, including Integra LifeSciences, Covidien, Medtronic, and Radionics. Dr. von Jako holds a Ph.D. in Biomedical Sciences from the University of Pécs, a M.S. degree in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology, and a double B.S. degree in Physics and Mathematics from Bates College. He resides in Lynnfield, Massachusetts and continues to serve as an independent director on the boards of NinePoint Medical, Inc. and nView medical Inc.
- Hadar Levy
Hadar Levy，自2022年8月起担任ReWalk Robotics Ltd.董事。利维先生在管理和财务方面拥有20多年的经验。Levy先生自2023年2月起担任Brainsway Ltd.的首席执行官，该公司是一家商业阶段的医疗设备公司，为精神疾病开发先进的非侵入性神经刺激疗法。在此之前，自2014年7月加入以来，他在Brainsway担任过多个高级管理职务，包括自2020年5月起担任高级副总裁兼首席运营官，并于2014年9月至2020年5月担任首席财务官。在加入Brainsway之前，Levy先生曾在Amdocs有限公司拉丁美洲分部担任财务经理，负责会计、财务报告、财务、投资组合管理和并购的财务支持。在加入Amdocs之前，他曾担任Notal Vision的首席财务官和业务发展，Notal Vision是一家医疗保健公司，研究和开发用于检测视网膜功能障碍和退化的医疗技术，负责所有财务职能，并领导包括与战略合作伙伴的并购活动在内的多轮财务股权交易。在担任这一职务之前，他曾担任GE Healthcare Israel的财务总监。利维先生的职业生涯始于德勤律师事务所。他拥有Bar-Ilan大学（以色列特拉维夫）的会计和经济学学士学位和法学硕士学位，并且是一名注册会计师。
Hadar Levy,has served on Rewalk Robotics Ltd. Board since August 2022. Mr. Levy has more than 20 years of experience in management and finance. Mr. Levy has served as the Chief Executive Officer of Brainsway Ltd., a commercial stage medical device company developing advanced noninvasive neurostimulation treatments for mental health disorders, since February 2023, and prior to that, held several senior management roles at Brainsway since joining in July 2014, including as Senior Vice President and Chief Operating Officer since May 2020, and as Chief Financial Officer from September 2014 to May 2020. Prior to joining Brainsway, Mr. Levy served as a finance manager in the Latin America Division at Amdocs Ltd., where he was responsible for accounting, financial reporting, treasury, portfolio management and finance support for Mergers & Acquisitions. Prior to Amdocs, he served as Chief Financial Officer & Business Development of Notal Vision, a healthcare company that researches and develops medical technologies for detecting retinal malfunction and deterioration, where he was responsible for all financial functions and led financial rounds of equity including M&A activities with strategic partners. Prior to this position, he served as Controller of GE Healthcare Israel. Mr. Levy began his career at Deloitte LLP. He holds a BA in Accounting and Economics, an LLM degree from Bar-Ilan University (Tel Aviv, Israel), and is a Certified Public Accountant.- Hadar Levy，自2022年8月起担任ReWalk Robotics Ltd.董事。利维先生在管理和财务方面拥有20多年的经验。Levy先生自2023年2月起担任Brainsway Ltd.的首席执行官，该公司是一家商业阶段的医疗设备公司，为精神疾病开发先进的非侵入性神经刺激疗法。在此之前，自2014年7月加入以来，他在Brainsway担任过多个高级管理职务，包括自2020年5月起担任高级副总裁兼首席运营官，并于2014年9月至2020年5月担任首席财务官。在加入Brainsway之前，Levy先生曾在Amdocs有限公司拉丁美洲分部担任财务经理，负责会计、财务报告、财务、投资组合管理和并购的财务支持。在加入Amdocs之前，他曾担任Notal Vision的首席财务官和业务发展，Notal Vision是一家医疗保健公司，研究和开发用于检测视网膜功能障碍和退化的医疗技术，负责所有财务职能，并领导包括与战略合作伙伴的并购活动在内的多轮财务股权交易。在担任这一职务之前，他曾担任GE Healthcare Israel的财务总监。利维先生的职业生涯始于德勤律师事务所。他拥有Bar-Ilan大学（以色列特拉维夫）的会计和经济学学士学位和法学硕士学位，并且是一名注册会计师。
- Hadar Levy,has served on Rewalk Robotics Ltd. Board since August 2022. Mr. Levy has more than 20 years of experience in management and finance. Mr. Levy has served as the Chief Executive Officer of Brainsway Ltd., a commercial stage medical device company developing advanced noninvasive neurostimulation treatments for mental health disorders, since February 2023, and prior to that, held several senior management roles at Brainsway since joining in July 2014, including as Senior Vice President and Chief Operating Officer since May 2020, and as Chief Financial Officer from September 2014 to May 2020. Prior to joining Brainsway, Mr. Levy served as a finance manager in the Latin America Division at Amdocs Ltd., where he was responsible for accounting, financial reporting, treasury, portfolio management and finance support for Mergers & Acquisitions. Prior to Amdocs, he served as Chief Financial Officer & Business Development of Notal Vision, a healthcare company that researches and develops medical technologies for detecting retinal malfunction and deterioration, where he was responsible for all financial functions and led financial rounds of equity including M&A activities with strategic partners. Prior to this position, he served as Controller of GE Healthcare Israel. Mr. Levy began his career at Deloitte LLP. He holds a BA in Accounting and Economics, an LLM degree from Bar-Ilan University (Tel Aviv, Israel), and is a Certified Public Accountant.